Prepare for your visit

Sandra S Werbel

Endocrinology, Diabetes & Metabolism · Gainesville, FL · NPI 1801976360

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$7,115.94

in general payments reported to CMS, 2019-2025 · $842 in 2025

The $842 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Who reported paying

General payments only, top 6 by amount.

Novo Nordisk INC $3,695.29
Boehringer Ingelheim Pharmaceuticals, INC. $512.20
Amgen INC. $397.56
Sanofi-Aventis U.S. LLC $367.79
Dexcom, INC. $340.72
Lilly USA, LLC $314.08

Drugs and devices associated with these payments

Ozempic Rybelsus Wegovy Jardiance Mounjaro Dexcom G7 Gss (161) Evenity Dexcom G6 Transmitter Zepbound Prolia Freestyle Libre 3 Synthroid

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Sandra Werbel listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/172306/sandra-s-werbel